A Study to Evaluate the Long-Term Safety and Tolerability of Faricimab in Participants With Diabetic Macular Edema

Inclusion Criteria:

• Previous enrollment in and completion of Study GR40349 (NCT03622580) or GR40398 (NCT03622593), without study or study drug discontinuation

• Ability to comply with the study protocol, in the investigator's judgment

• For women of childbearing potential: agreement to remain abstinent or use acceptablecontraceptive methods that result in a failure rate of <1% per year during thetreatment period and for at least 3 months after the final dose of study treatment

Exclusion Criteria:

• Pregnant or breastfeeding, or intending to become pregnant during the study orwithin 3 months after the final intravitreal injection of faricimab

• Presence of other ocular diseases that give reasonable suspicion of a disease orcondition that contraindicates the use of faricimab, that might affectinterpretation of the results of the study or that renders the patient at high riskfor treatment complications

• Presence of other diseases, metabolic dysfunction, or clinical laboratory findinggiving reasonable suspicion of a disease or condition that contraindicates the useof faricimab and that might affect interpretation of the results of the study orthat renders the patient at high risk of treatment complications

• History of a severe allergic reaction or anaphylactic reaction to a biologic agentor known hypersensitivity to any component of the faricimab injections, studytreatment procedure, dilating drops, or any of the anesthetic and antimicrobialpreparations used by a patient during the study

• Requirement for continuous use of any medications or treatments indicated asprohibited therapy